NET Therapy in the Era of PRRT

Course overview

UAN: 0018-0000-20-204-H01-P & T RELEASE: 04/13/2020 EXPIRE: 04/13/2023 CREDITS: 1.0 LEARNING OBJECTIVES: 1. Share a common framework for classifying neuroendocrine neoplasms. 2. Review data and experience on diagnosis of NETs and treatment options depending on grade, stage, and primary site. NOTE: An annual subscription for Purdue's nuclear pharmacy re-certification program provides access to both the continuing education component of the program and the "Radiopharmacy Portal" a reference resource for practitioners. Subscriptions to the continuing educational offerings, which have been accredited through ACPE and BPS, can be purchased for an annual fee of $195 for nuclear pharmacists and $95 for nuclear pharmacy technicians.